BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/3/2026 3:27:48 AM | Browse: 2 | Download: 0
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Khellaf Amalou, Ryma Rekab, Nada Benmellouka, Boutheina Derbal, Ahlem Belloula, Hana Chetroub, Fadel Sabrina, Farid Belghanem and Khadidja Saidani |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Khellaf Amalou, Assistant Professor, PhD, Department of Gastroenterology, Mohamed Seghir Nekkache, No. 246 Kouba, Algiers 16000, Algeria. amalou_kh@yahoo.fr |
| Key Words |
Hepatitis B; Treatment; Discontinuation; Relapse; Re-treatment |
| Core Tip |
Prolonged therapy remains the recommended method for patients with chronic hepatitis B. Nonetheless, concerns about treatment adherence and economic strain, particularly in resource-constrained areas, combined with research indicating that virological and clinical remission persists in non-cirrhotic patients after treatment cessation, prompted the development of nucleos(t)ide analog cessation guidelines for specific patients. However, the discontinuation of nucleos(t)ide analog is still a contested question. The median duration until recurrence was 11 months. The cumulative virological relapse rates, defined as chronic hepatitis B deoxyribonucleic acid over 2000 IU/mL, were 25%, 52%, 58%, and 61% at 6 months, 12 months, 24 months, and 36 months, respectively. The cumulative retreatment rates at 6 months, 12 months, 24 months, and 36 months were 19%, 25%, 28%, and 35%, respectively. Histologic fibrosis score > 2 is the unique factor for retreatment. |
| Citation |
Amalou K, Rekab R, Benmellouka N, Derbal B, Belloula A, Chetroub H, Sabrina F, Belghanem F, Saidani K. Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study. World J Virol 2026; In press
DOI: https://doi.org/10.5501/wjv.120124
|
 |
Received |
|
2026-03-04 03:33 |
 |
Peer-Review Started |
|
2026-03-04 03:35 |
 |
First Decision by Editorial Office Director |
|
2026-04-16 08:15 |
 |
Return for Revision |
|
2026-04-16 08:15 |
 |
Revised |
|
2026-06-02 22:31 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-07-03 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-07-03 03:27 |
 |
Articles in Press |
|
2026-07-03 03:27 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.